Effectiveness and safety of spesolimab in treating generalized pustular psoriasis: A comparative analysis of randomized controlled trials.
作者信息
Duvvuri Sai Praneeth, Burri Rithwik Goud, Ch Annie Monica, Meduri Krishna Chaitanya, Damineni Ujwala
机构信息
Department of General Medicine, Maheshwara Medical College and Hospital, Hyderabad, Telangana, India.
出版信息
Indian J Pharmacol. 2024 Sep 1;56(5):365-366. doi: 10.4103/ijp.ijp_240_24. Epub 2024 Dec 16.
Abstract
摘要
相似文献
1
Effectiveness and safety of spesolimab in treating generalized pustular psoriasis: A comparative analysis of randomized controlled trials.司库奇尤单抗治疗泛发性脓疱型银屑病的有效性和安全性：随机对照试验的比较分析
Indian J Pharmacol. 2024 Sep 1;56(5):365-366. doi: 10.4103/ijp.ijp_240_24. Epub 2024 Dec 16.
2
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.斯帕利单抗治疗泛发性脓疱型银屑病亚洲患者的疗效和安全性：Effisayil™ 1 研究的随机、双盲、安慰剂对照结果。
J Dermatol. 2023 Feb;50(2):183-194. doi: 10.1111/1346-8138.16609. Epub 2022 Oct 25.
3
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.在随机、安慰剂对照的 Effisayil 1 研究中，spesolimab 治疗泛发性脓疱型银屑病发作，可迅速和持续改善全身性脓疱性银屑病医师总体评估评分。
J Am Acad Dermatol. 2023 Jul;89(1):36-44. doi: 10.1016/j.jaad.2023.02.040. Epub 2023 Mar 2.
4
Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.斯佩索利单抗治疗泛发性脓疱型银屑病：两项关键性临床试验的综述，支持该药在美国的初始监管批准。
Front Immunol. 2024 Jul 22;15:1359481. doi: 10.3389/fimmu.2024.1359481. eCollection 2024.
5
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.Effisayil™ 2的设计：一项关于司帕索利单抗预防泛发性脓疱型银屑病患者病情发作的随机、双盲、安慰剂对照研究。
Dermatol Ther (Heidelb). 2023 Jan;13(1):347-359. doi: 10.1007/s13555-022-00835-6. Epub 2022 Nov 5.
6
Analysis of the German Compassionate Use Program on spesolimab in patients with generalized pustular psoriasis: evidence outside of clinical trials.德国司库奇尤单抗用于泛发性脓疱型银屑病患者的同情用药计划分析：临床试验之外的证据
Eur J Dermatol. 2024 Dec 1;34(6):643-650. doi: 10.1684/ejd.2024.4785.
7
Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.在 Effisayil 1 研究中，spesolimab 治疗泛发性脓疱型银屑病发作的疗效在预先指定的患者亚组中。
Exp Dermatol. 2023 Aug;32(8):1279-1283. doi: 10.1111/exd.14824. Epub 2023 May 4.
8
Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares.司佩索利单抗治疗泛发性脓疱型银屑病发作
J Drugs Dermatol. 2025 Mar 1;24(3):242-245. doi: 10.36849/JDD.8322.
9
Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial.司库奇尤单抗治疗泛发性脓疱型银屑病患者的疗效和安全性：Effisayil 1试验中中国患者的亚组分析
Dermatol Ther (Heidelb). 2023 Dec;13(12):3097-3110. doi: 10.1007/s13555-023-01037-4. Epub 2023 Oct 16.
10
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1.斯佩索利单抗可减轻泛发性脓疱型银屑病的炎症：EFFISAYIL 1中发作期治疗的分子特征
J Invest Dermatol. 2025 Mar;145(3):573-582.e8. doi: 10.1016/j.jid.2024.05.034. Epub 2024 Jul 14.
引用本文的文献
1
Systemic Psoriasis: From Molecular Mechanisms to Global Management Strategies.全身性银屑病：从分子机制到全球管理策略
Clin Rev Allergy Immunol. 2025 Aug 7;68(1):79. doi: 10.1007/s12016-025-09089-4.
本文引用的文献
1
Trial of Spesolimab for Generalized Pustular Psoriasis.特索利单抗治疗泛发性脓疱型银屑病的试验。
N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563.
2
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.脓疱型银屑病：全身性脓疱型银屑病中 spesolimab 的分子途径和作用。
J Allergy Clin Immunol. 2022 Apr;149(4):1402-1412. doi: 10.1016/j.jaci.2021.09.035. Epub 2021 Oct 20.
3
Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity.泛发性脓疱型银屑病：先天性免疫与适应性免疫的分歧
Int J Mol Sci. 2021 Aug 22;22(16):9048. doi: 10.3390/ijms22169048.
4
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.司妥昔单抗（一种抗白细胞介素-36受体抗体）治疗掌跖脓疱病患者：一项IIa期、多中心、双盲、随机、安慰剂对照试验的结果
Dermatol Ther (Heidelb). 2021 Apr;11(2):571-585. doi: 10.1007/s13555-021-00504-0. Epub 2021 Mar 4.
Zotero 插件